Implication of the ADCY1 Gene in Lithium Response in Bipolar Disorder by Genome-Wide Association Meta-Analysis.
Researchers
Kai Yao, Ayeda Nadeem, Tracey van der Veen, Johan H Thygesen, Lina Jonsson, Jie Song, Mikael Landén, Nick Bass, Andrew McQuillin
Abstract
Efforts to examine the influence of genetics in the efficacy of lithium using genome-wide association studies (GWAS) have identified several loci. Here, we report new cases and meta-analyses to combine previous efforts. We report data from 1259 participants with bipolar disorder (BD) recruited at University College London who had been treated with lithium. The data come from three waves of genotyping on different arrays. The GWAS data from each array was analysed separately and then meta-analysed with two published lithium response GWAS datasets. Post-GWAS analyses were conducted to examine lithium response heritability and its genetic correlations with other traits. We also attempted to replicate past polygenic risk scores (PRS) results. SNP rs116927879 (A/G) was associated with lithium response at a genome-wide significance level (p = 4.509 × 10<sup>-08</sup>) with a consistent effect across all cohorts. rs116927879 is located on chromosome 7 and maps to the protein-coding gene ADCY1 and two pseudo-genes, GTF2IP13 and SEPT7P2. The sQTL results suggested that rs116927879 genotypes may influence the splicing of ADCY1 across different brain regions. We estimated the SNP heritability (h<sup>2</sup>) for good lithium response as 20.3% and 15.6% for subjective/objective response definitions, respectively. We did not observe any genetic correlation or PRS association between the lithium response and schizophrenia or major depression disorder. However, we found weak evidence to suggest that males are more likely to be good responders. Our GWAS identifies a genome-wide significant finding and provides updated heritability estimates for lithium efficacy.Source: PubMed (PMID: 43065173)View Original on PubMed